EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Serum CCL18 May Reflect Multiorgan Involvement with Poor Outcome in Systemic Sclerosis

Kristóf Filipánits iD, Gabriella Nagy iD, Dávid Kurszán Jász iD, Tünde Minier iD, Diána Simon, Szabina Erdő-Bonyár iD, Tímea Berki iD, Gábor Kumánovics iD

Biomolecules · 2026

DOI: 10.3390/biom16010136 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, 2026. Verfasst von Kristóf Filipánits und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Medical School, University of Pécs, 7632 Pécs, Hungary. Hauptthemen laut MEDLINE: Scleroderma, Systemic, Chemokines, CC. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PEPSYS GINOP-2.3.2, European Scleroderma Trials and Research Group, National Research, Development and Innovation Fund of Hungary.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Serum C–C motif chemokine ligand 18 (seCCL18) in systemic sclerosis (SSc) has been primarily associated with progressive interstitial lung disease (SSc-ILD) and mortality. However, its relationship with non-pulmonary organ involvement, disease activity, and long-term outcome has not been comprehensively evaluated. We therefore examined the clinical relevance of seCCL18 in a single-center SSc cohort.

Methods

A total of 151 patients with SSc (83 diffuse cutaneous (dcSSc), 68 limited cutaneous SSc (lcSSc); median (IQR) disease duration: 9 (4;16) years) and 47 age- and sex-matched healthy controls (HCs) were enrolled. Serum CCL18 concentrations were measured by enzyme-linked immunosorbent assay. Elevated seCCL18 was defined as >130 ng/mL (mean + 2 SD of the healthy control group). Organ involvement and disease activity (EUSTAR Activity Index, EUSTAR-AI) were assessed at baseline, while survival was analysed longitudinally.

Results

Patients with SSc had significantly higher seCCL18 levels than HCs (mean ± SD: 99.9 ± 43.2 vs. 75.0 ± 27.5 ng/mL, p < 0.01). Elevated seCCL18 was associated with SSc-ILD (81.1% vs. 60.5%, p = 0.022), reduced forced vital capacity (FVC < 70%: 16.2% vs. 3.5%, p = 0.006), and reduced diffusing capacity for carbon monoxide (DLCO < 70%: 80.6% vs. 54.4%, p = 0.005). Higher seCCL18 levels were observed in patients with myocardial disease (104.8 ± 41.8 vs. 83.8 ± 44.2 ng/mL, p = 0.008), left ventricular diastolic dysfunction (107.1 ± 40.5 vs. 84.5 ± 45.0 ng/mL, p < 0.001), and oesophageal involvement (110.7 ± 38.3 vs. 93.3 ± 43.1 ng/mL, p = 0.009). SeCCL18 levels above the cut-off were more frequently associated with tendon friction rubs (51.4% vs. 27.4%, p = 0.007), active disease (EUSTAR-AI ≥ 2.5: 73% vs. 44%, p = 0.002), and elevated inflammatory markers (CRP > 5 mg/L: 51.4% vs. 19.3%, p < 0.001; ESR > 28 mm/h: 37.8% vs. 18.4%, p = 0.015). During a median follow-up of 87 months, 22 patients (15%) died. Elevated baseline seCCL18 predicted poorer survival in univariate analysis (log-rank p = 0.013) and remained an independent predictor of mortality in multivariable Cox regression (HR 1.789; 95% CI 1.133–2.824; p = 0.013), together with declining DLCO and reduced six-minute walk test performance.

Conclusions

Elevated seCCL18 may identify patients with systemic sclerosis who exhibit a more severe multisystem phenotype, including cardiopulmonary, gastrointestinal, and musculoskeletal involvement, increased inflammatory activity, and reduced long-term survival. These findings suggest that seCCL18 may have some clinical utility as a prognostic biomarker reflecting widespread disease involvement beyond the lungs, even in patients with long-standing disease; however, the lack of an established cut-off value requires further validation in prospective, multicentre studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Scleroderma, SystemicChemokines, CCHumansFemaleMaleMiddle AgedAdultBiomarkersPrognosisCase-Control StudiesLung Diseases, InterstitialAged

Stichwörter der Autor:innen

CCL18disease activityinterstitial lung diseasemultiorgan involvementprognosisserum biomarkersurvivalsystemic sclerosis

Substanzen

CCL18 protein, humanChemokines, CCBiomarkers

Autor:innen und Institutionen

  • Department of Rheumatology and Immunology, Medical School, University of Pécs, 7632 Pécs, Hungary.
  • Department of Immunology and Biotechnology, Medical School, University of Pécs, 7632 Pécs, Hungary.

ORCID-Profile: Kristóf Filipánits, Gabriella Nagy, Dávid Kurszán Jász, Tünde Minier, Szabina Erdő-Bonyár, Tímea Berki, Gábor Kumánovics

Förderung

  • PEPSYS GINOP-2.3.2
  • European Scleroderma Trials and Research Group
  • National Research, Development and Innovation Fund of Hungary
  • University Research Fellowship Programme of the Ministry for Culture and Innovation Hungary
  • Hungarian National Research, Development and Innovation Fund

Zitieren

APA

Filipánits, K., Nagy, G., Jász, D. K., Minier, T., Simon, D., Erdő-Bonyár, S., Berki, T., & Kumánovics, G. (2026). Serum CCL18 May Reflect Multiorgan Involvement with Poor Outcome in Systemic Sclerosis. Biomolecules. https://doi.org/10.3390/biom16010136

Vancouver

Filipánits K, Nagy G, Jász DK, Minier T, Simon D, Erdő-Bonyár S, et al. Serum CCL18 May Reflect Multiorgan Involvement with Poor Outcome in Systemic Sclerosis. Biomolecules. 2026. doi:10.3390/biom16010136

BibTeX
@article{Filipnits2026,
  author = {Filipánits, Kristóf and Nagy, Gabriella and Jász, Dávid Kurszán and Minier, Tünde and Simon, Diána and Erdő-Bonyár, Szabina and Berki, Tímea and Kumánovics, Gábor},
  title = {Serum CCL18 May Reflect Multiorgan Involvement with Poor Outcome in Systemic Sclerosis},
  journal = {Biomolecules},
  year = {2026},
  doi = {10.3390/biom16010136}
}
Kostenlos starten →